Investor Relations

Here you will find details on our share as well as detailed information on key figures, annual and quarterly results, IR events and much more.

Business Description

HAEMATO AG, founded in 1993, is a listed pharmaceutical company. The company is listed on the Entry Standard (Open Market) of the Frankfurt Stock Exchange and is based in Schönefeld.
HAEMATO AG is active in the pharmaceutical sector. The focus of business activities is on the growth markets for off-patent and patent-protected drugs and the manufacture of medications. The focus is on therapies for cancer, HIV and other chronic diseases.

Company Information

First trading day10.05.1993
Accounting standardHGB / IFRS
Runterminated as of 31.12.2017
Management BoardUwe Zimdars, CEO
Daniel Kracht, CFO
Supervisory Board Andrea Grosse, Chairwoman of the supervisory board
Prof. Dr. Dr. Sabine Meck, Deputy chairwoman of the supervisory board
Dr. Marion Braun, Member of the supervisory board

Information on Trade Data

SpecialistODDO SEYDLER BANK AG,
Schillerstraße 27, 60313 Frankfurt am Main
Designated SponsorICF Kursmakler AG,
Kaiserstraße 1, D-60311 Frankfurt am Main
Listing PartnerICF Kursmakler AG,
Kaiserstraße 1, D-60311 Frankfurt am Main
DSPICF Kursmakler AG,
Kaiserstraße 1, D-60311 Frankfurt am Main
Number of shares22.867.154
Stock capital 22.867.154,00 €
Freefloat50,1 %
Shareholder structureMPH Health Care AG for instance 49,9 %
(as of: 30.09.2018)

HAEMATO AG

HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany

Phone: +49-30 897 30 86 70
Telefax: +49-30 897 30 86 79
E-Mail: info@haemato.ag